Bristol-Myers Squibb (NYSE: BMY) reported Q2 EPS of $0.69, $0.03 better than the analyst estimate of $0.66. Revenue for the quarter came in at $4.9 billion versus the consensus estimate of $4.6 billion.

“During the second quarter we delivered strong sales and earnings growth, achieved important regulatory milestones with Opdivo across multiple types of cancer, and further advanced our leadership in Immuno-Oncology through the breadth of the clinical data we presented at ASCO,” said Giovanni Caforio, M.D., chief executive officer, Bristol-Myers Squibb. “I am confident strong performance of our in-line products, progress with our diversified pipeline and our focused approach to business development position us well for continued success.”

GUIDANCE:

Bristol-Myers Squibb sees FY2016 EPS of $2.55-$2.65, versus the consensus of $2.60.

For earnings history and earnings-related data on Bristol-Myers Squibb (BMY) click here.